If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-16. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== Overview == The metabolic processes of all organisms can only take place in very specific physical and chemical environments. The conditions vary with each organism, and also with whether the chemical processes take place inside the cell or in the interstitial fluid bathing the cells. The best-known homeostatic mechanisms in humans and other mammals are regulators that keep the composition of the extracellular fluid (or the "internal environment") constant, especially with regard to the temperature, pH, osmolality, and the concentrations of sodium, potassium, glucose, carbon dioxide, and oxygen. However, a great many other homeostatic mechanisms, encompassing many aspects of human physiology, control other entities in the body. Where the levels of variables are higher or lower than those needed, they are often prefixed with hyper- and hypo-, respectively such as hyperthermia and hypothermia or hypertension and hypotension.
== Background == Plants and animals alike both use small polypeptides for signaling in cell-to-cell communication. CLAVATA3/Embryo Surrounding Region-Related, also known as a plant peptide hormone, signaling is important for cell to cell signaling but also long distance communication. These two actions are especially important for plant cells because they are stationary and must perform cell expansion. In multicellular organisms, cell-to-cell communication has been found to be very crucial for many growth processes that occur inside the organism. The 12 or 13 amino acid polypeptides are the mature forms of the CLE proteins that are derived from the conserved CLE domains. More and more CLE genes are being identified with more research being conducted in this area. CLE genes have not only been found in seed plants but also in lycophytes, bryophytes, and green algae.
Within the international relations literature, international organizations facilitate cooperation between states by reducing transaction costs, providing information, making commitments more credible, establishing focal points for coordination, facilitating the principle of reciprocity, extending the shadow of the future, and enabling interlinkages of issues, which raises the cost of noncompliance. States may comply with the decisions of international organizations, even when they do not want to, for rational cost-benefit calculations (to reap concrete rewards of future cooperation and avoid punishment) and normative reasons (social learning and socialization). International organizations vary in terms of: inclusive or exclusive membership; broad or narrow scope; equal or unequal control by members; precision and flexibility of rules; hard or soft obligations; and delegation of power to the international organization. Other examples of international organizations include the UN General Assembly, the World Trade Organization, the African Development Bank, the UN Economic and Social Council, the UN Security Council, the Asian Development Bank, the International Bank for Reconstruction and Development, the International Monetary Fund, the International Finance Corporation, the Inter-American Development Bank, and the United Nations Environment Programme.
== Notes == "EMDB-1067: Ribosomal 80S-eEF2-sordarin complex from S. cerevisiae - EM Navigator". emnavi.protein.osaka-u.ac.jp. Retrieved 2009-08-06.{{cite web}}: CS1 maint: deprecated archival service (link) Giavalisco P, Wilson D, Kreitler T, et al. (March 2005). "High heterogeneity within the ribosomal proteins of the Arabidopsis thaliana 80S ribosome". Plant Mol. Biol. 57 (4): 577–591. Bibcode:2005PMolB..57..577G. doi:10.1007/s11103-005-0699-3. hdl:11858/00-001M-0000-0010-86C6-1. PMID 15821981. S2CID 14500573. "Ribosomes". www.cs.stedwards.edu. Archived from the original on 2009-03-20. Retrieved 2009-08-06.
mTOR Complex 2 (mTORC2) is composed of mTOR, rapamycin-insensitive companion of mTOR (RICTOR), MLST8, and mammalian stress-activated protein kinase interacting protein 1 (mSIN1). mTORC2 has been shown to function as an important regulator of the actin cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα). mTORC2 also phosphorylates the serine/threonine protein kinase Akt/PKB on serine residue Ser473, thus affecting metabolism and survival. Phosphorylation of Akt's serine residue Ser473 by mTORC2 stimulates Akt phosphorylation on threonine residue Thr308 by PDK1 and leads to full Akt activation. In addition, mTORC2 exhibits tyrosine protein kinase activity and phosphorylates the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (InsR) on the tyrosine residues Tyr1131/1136 and Tyr1146/1151, respectively, leading to full activation of IGF-IR and InsR.
Sources: en.wikipedia.org
Medieval philosophers who used Aristotelian concepts frequently distinguished between substantial forms and accidental forms. A substance necessarily possesses at least one substantial form. It may also possess a variety of accidental forms. For Aristotle, a "substance" (ousia) is an individual thing—for example, an individual man or an individual horse. Within every physical substance, the substantial form determines what kind of thing the physical substance is by actualizing prime matter as individualized by the causes of that thing's coming to be. For instance, the chick comes to be when the substantial form of chickens actualizes the hen's egg and that actualization is possible insofar as that egg is in potency to being actualized both as a chicken due to the receptivity of its prime matter to the substantial form of chickens and into a chick with certain colored feathers due to the individualization of the egg given by its parents. So while the individualized matter determines individualized properties, the substantial form determines essential properties. The substantial form of a substance S consists of its essence and essential properties (the properties that S needs in order to be the kind of substance that S is). Substantial change destroys the ability of a substantial form to actualize individualized prime matter without affecting prime matter's ability to be actualized by a new substantial form; e.g., when the wolf eats the chick, the chick's rearranged matter becomes part of the wolf, and is thence animated by the wolf's substantial form.
=== Legal status === The US Food and Drug Administration (FDA) granted the application for dupilumab priority review designation and in March 2017, the FDA approved dupilumab injection to treat adults with moderate-to-severe eczema. The FDA granted the application breakthrough therapy designation.
=== 1945 === February 4–11: The Yalta Conference in Crimea, RSFSR, with US President Franklin D. Roosevelt, British Prime Minister Winston Churchill and Soviet leader Joseph Stalin, and their top aides. Main attention is deciding the post-war status of Germany. The Allies of World War II (the United States, the Soviet Union, United Kingdom and also France) divide Germany into four occupation zones. The Allied nations agree that free elections are to be held in Poland and all countries occupied by Nazi Germany. In addition, the new United Nations are to replace the failed League of Nations. March 6: The Soviet Union installs a puppet government in Romania. March 7: Josip Broz Tito is installed as the head of the provisional government of Democratic Federal Yugoslavia. March–April: U.S. and Britain outraged as Stalin excludes them from a role in Poland and turns Poland over to a Communist puppet government he controls. March–April: Stalin is outraged at inaccurate reports about Operation Sunrise that American Office of Strategic Services in Switzerland is negotiating a surrender of German forces; he demands a Soviet general be present at all negotiations. Roosevelt vehemently denies the allegation but closes down the operation in Switzerland. A Soviet general is present at the negotiations in northern Italy that lead to surrender. April 12: Roosevelt dies; Vice President Harry S. Truman takes over with little knowledge of current diplomatic efforts, no knowledge of the atomic bomb, and a bias against Russia. April 28: Benito Mussolini dies. April 30: Adolf Hitler dies.
The 1970 census showed that white people still comprised most of Detroit's population. However, by the 1980 census, white people had left at such a high rate that the city had gone from 55 percent to 34 percent white within a decade. The decline was even starker than this suggests, considering that when Detroit's population reached its all-time high in 1950, the city was 83 percent white. Economist Walter E. Williams writes that the decline was sparked by the policies of Mayor Young, who Williams claims discriminated against whites. By contrast, urban affairs experts largely blame federal court decisions that decided against NAACP lawsuits and refused to challenge the legacy of housing and school segregation – particularly the case of Milliken v. Bradley, which was appealed up to the Supreme Court. The District Court in Milliken had initially ruled that it was necessary to actively desegregate Detroit and its suburban communities in one comprehensive program. The city was ordered to submit a "metropolitan" plan that would eventually encompass fifty-four separate school districts, busing Detroit children to suburban schools and suburban children into Detroit. The Supreme Court reversed this in 1974. In his dissent, Justice William O. Douglas argued that the majority's decision perpetuated "restrictive covenants" that "maintained ... black ghettos". Gary Orfield and Susan E.
Action Half-Life is a mod for the first-person shooter video game Half-Life. It strives to simulate action movies, especially those directed by John Woo. Action Half-Life is the second mod in the "Action" series. The first was Action Quake 2 and the third was Action Unreal Tournament 2004.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.